Decoy Therapeutics Inc. develops preclinical peptide conjugate therapeutics built around Designable Multi-Antivirals, or D-MAVs, and its proprietary IMP3ACT platform. Company news centers on AI-enabled peptide design, rapid synthesis and manufacturing, respiratory-virus programs, and scientific presentations tied to pan-coronavirus and broad antiviral discovery efforts.
Recurring updates also include computational biology collaborations, non-dilutive program support, investor communications, capital-market actions, and Nasdaq listing-compliance matters. The company's public updates frame Decoy as a preclinical biotechnology issuer focused on respiratory viruses, with earlier company materials also referencing GI cancer pipeline work.
Decoy Therapeutics (DCOY) expects to file a clinical trial application for its lead pan-coronavirus candidate in the second half of 2027. The planned CTA or IND filing would support a Phase 1 trial. An optimized candidate showed potential for once-weekly dosing in preclinical studies, compared with daily dosing for earlier candidates.
Decoy plans a subsequent Phase 2a human challenge trial at hVivo and is evaluating manufacturing locations and pulmonary delivery systems. It is also exploring a pan-filovirus program and pursuing non-dilutive funding and collaborations. Cash was $8.1 million at September 30, 2026, including approximately $2.5 million in restricted Gates Foundation grant funding.
ACCESS Newswire (ACCS) is among eight public companies presenting at The Small Cap Showcase investor conference in New York City. The lineup also includes First Phosphate, Cerrado Gold, Coiled Therapeutics, Decoy Therapeutics, Firefly Neuroscience, Eco Wave Power and Sparta Commercial Services. The event includes company presentations and one-on-one investor meetings; ACCESS Newswire is scheduled to present at 3:00 PM Eastern Time, with times subject to change.
Decoy Therapeutics (DCOY) will present at The Small Cap Showcase in New York City on October 1, 2026. Chief Executive Officer Rick Pierce will deliver a corporate overview at 11:30 a.m. ET and participate in one-on-one meetings with investors during the conference.
Decoy Therapeutics (DCOY) reported preclinical DCOY-CoV data supporting potential once-weekly intranasal dosing for its coronavirus program.
After a single dose, drug levels in nasal mucosal and lung tissue remained above concentrations designed for antiviral activity for up to seven days. These pharmacokinetic measurements track drug levels, not protection in people. DCOY-CoV is designed to target endemic human coronaviruses, including SARS-CoV-2, in people at high risk of serious illness. Decoy expects the program to enter clinical trials in 2027. Chief Technology Officer Michael Lipp will present the initial dataset at the Boulder Peptide Symposium on September 29.
Decoy Therapeutics (DCOY) corrected details of its previously announced warrant inducement transaction dated September 22, 2026. The company now states that the new unregistered warrants to purchase up to 2,368,868 shares of common stock will become exercisable immediately upon issuance, rather than upon receipt of stockholder approval as previously indicated.
The new warrants are not subject to stockholder approval and will expire five years from their issuance date. All other terms and information from the original warrant inducement press release remain unchanged.
Decoy Therapeutics (DCOY) entered into a warrant inducement agreement expected to generate approximately $3.85 million in gross proceeds.
An existing institutional investor will immediately exercise 1,184,434 Series B Milestone Warrants issued June 29, 2026 at a reduced exercise price of $3.25 per share. In connection with this, the exercise price of Decoy’s outstanding Series A and Series C Milestone Warrants will also be reduced from $5.91 to $3.25 per share. The company plans to use net proceeds for working capital and general corporate purposes.
In consideration for the full exercise, the investor will receive in a private placement New Warrants to purchase up to 2,368,868 shares at $3.25 per share, exercisable after stockholder approval and expiring five years from initial exercise. Closing is expected on or about September 23, 2026, subject to customary conditions.
Decoy Therapeutics (DCOY) outlined a refined strategy to develop its D‑MAV™ antivirals into a pan‑filovirus program via the U.S. FDA Animal Rule pathway, supported primarily by non‑dilutive government grants and biodefense partnerships.
A first‑generation de novo filovirus fusion inhibitor generated with the IMP³ACT™ engine showed an IC50 of 1.56 μM against wild‑type Ebola Zaire in cell assays, over five‑fold more potent than Decoy’s pan‑coronavirus lead and about seven‑fold more potent than benchmark antiviral remdesivir, and also demonstrated activity against Marburg virus with an IC50 of 1.04 μM. Decoy is running generative design campaigns to create a single pan‑filovirus D‑MAV for pre‑ and post‑exposure prophylaxis and aims to engineer molecules for extended tissue residence and weekly dosing. Eligible filovirus approvals could earn a transferable FDA Priority Review Voucher, with recent market values of $100–$180 million.
Decoy Therapeutics (DCOY) is refocusing its corporate strategy to advance a pan-filovirus D-MAV™ program toward potential FDA approval via the Animal Rule pathway, while seeking non-dilutive government grants and biodefense partnerships.
A first-generation de novo filovirus fusion inhibitor, designed using the IMP³ACT™ AI/ML engine, showed low-micromolar in vitro potency against wild-type Ebola Zaire with >5-fold improved activity versus Decoy’s pan-coronavirus lead and a 7-fold improvement over remdesivir, and also demonstrated activity against Marburg virus. The company aims to create a single broad-spectrum D-MAV for pre‑ and post‑exposure prophylaxis across human filoviruses, engineered for extended tissue residence and long plasma half-life. Under the Animal Rule, efficacy would be demonstrated in animal models with human safety and PK data, potentially enabling Strategic National Stockpile procurement and eligibility for a Tropical Disease Priority Review Voucher, which recent transactions value at $100–$180 million.
Decoy Therapeutics (DCOY) will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City on September 9–10, 2026. Chief Executive Officer Rick Pierce is scheduled to deliver a corporate overview on Thursday, September 10, 2026 at 1:45 p.m. at The Westin New York Grand Central and will also participate in one-on-one investor meetings during the event.
Decoy Therapeutics (Nasdaq: DCOY) announced that its intellectual property portfolio for Designable Multi-Antivirals (D-MAVs™) and the IMP³ACT™ design platform now includes seven patent families. The portfolio comprises one granted U.S. patent and 19 pending applications across the United States, Australia, Canada, China, Europe, Japan, and New Zealand.
According to Decoy Therapeutics, these patents and applications, all solely owned by the company, cover antiviral peptide conjugate compositions, automated flow manufacturing methods and linker chemistries, formulations, engineered D-MAVs targeting conserved class I viral fusion features, uses against multiple paramyxoviruses, and newly filed methods for designing class I fusion peptides underlying the IMP³ACT platform.